Zynex Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Zynex (NASDAQ: ZYXI) reported Q2 2024 financial results with revenue increasing 11% to $49.9 million. Key highlights include:

- Q2 2024 orders up 20% year-over-year, marking the ninth consecutive quarter of record orders
- Net income of $1.2 million; Diluted EPS $0.04
- Year-to-date cash flow from operations up 20% to $3.2 million
- $2.2 million in share repurchases during Q2

The company revised its 2024 guidance, now expecting revenue growth of approximately 9% compared to 2023. For Q3 2024, Zynex estimates revenue of at least $50 million and Diluted EPS of at least $0.05. The full year 2024 outlook projects net revenue of at least $200 million with Diluted EPS of at least $0.20 per share.

Positive

• Q2 2024 orders increased 20% year-over-year, reaching a record high for the ninth consecutive quarter
• Q2 2024 revenue grew 11% year-over-year to $49.9 million
• Gross profit margin improved to 80% in Q2 2024, up from 79% in Q2 2023
• Year-to-date cash flow from operations increased 20% to $3.2 million
• Company repurchased $2.2 million of common stock in Q2 2024

Negative

• Q2 2024 revenue of $49.9 million was lower than previous guidance of $52.0 million
• Net income decreased to $1.2 million in Q2 2024 from $3.4 million in Q2 2023
• Diluted EPS declined to $0.04 in Q2 2024 from $0.09 in Q2 2023
• Adjusted EBITDA decreased to $3.5 million in Q2 2024 from $4.0 million in Q2 2023
• Company revised down its 2024 revenue growth guidance to approximately 9% from previous estimates

Financial Analyst

Zynex's Q2 2024 results present a mixed picture. While revenue increased 11% year-over-year to $49.9 million, it fell short of the company's previous guidance of $52.0 million. This shortfall was primarily attributed to a reduction in sales representatives and a shift in product mix.

The company's focus on profitable growth is evident, with a 20% increase in orders year-over-year. However, this hasn't translated directly to bottom-line growth, as net income decreased to $1.2 million ($0.04 per diluted share) from $3.4 million ($0.09 per diluted share) in Q2 2023.

The shift in product mix towards private-labeled pain management products is noteworthy. While this diversifies revenue streams, these one-time sales lack the recurring revenue model of Zynex's electrotherapy products. This change could impact future revenue predictability and growth rates.

Zynex's revised guidance for 2024, projecting a 9% revenue increase to $200 million, down from previous estimates, reflects these challenges. However, the company's expectation to return to 20% top-line growth in its pain management division by 2025 suggests confidence in its long-term strategy.

The company's continued share repurchase program, with $2.2 million of stock bought back in Q2 and $70.0 million over the past two years, indicates management's belief in the company's value proposition.

Medical Device Industry Expert

Zynex's Q2 2024 results highlight the evolving landscape of the medical device industry, particularly in pain management. The company's 20% year-over-year increase in orders suggests growing market acceptance of non-invasive pain management solutions. This aligns with broader industry trends towards minimally invasive and drug-free treatment options.

The company's strategy to diversify its product portfolio with private-labeled pain management products is a double-edged sword. While it expands Zynex's market presence, it also introduces volatility into the revenue model. The medical device industry typically values recurring revenue streams, which Zynex's core electrotherapy products provide. The shift towards one-time sales products may raise concerns among industry analysts about long-term revenue stability.

Zynex's focus on sales rep productivity and willingness to separate underperforming representatives demonstrates a mature approach to sales force management. This is important in the medical device industry, where relationships with healthcare providers are key to driving adoption and sales.

The mention of pending FDA approvals for next-generation devices is particularly intriguing. In the medical device industry, new product launches can significantly impact a company's market position and growth trajectory. Investors and industry watchers will likely be keen to see how these potential new products could differentiate Zynex in the competitive pain management market.

Q2 2024 Revenue Increased 11% to $49.9 Million

ENGLEWOOD, Colo., July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024.

Key Second Quarter Highlights and Business Update

• Q2 2024 orders increased 20% year-over-year, the highest number of orders in Company history for the ninth consecutive quarter.
• Q2 2024 revenue increased 11% year-over-year to $49.9 million; Q2 2024 revenue was lower than previous guidance of $52.0 million primarily related to a reduction in sales representatives and forgoing current sales to focus on profitable growth and rep productivity, and a changing product mix.
• Q2 2024 net income of $1.2 million; Diluted EPS $0.04.
• Year-to-date cash flow from operations of $3.2 million, a 20% year-over-year increase.
• Repurchased $2.2 million of the Company's common stock in Q2 2024.

Management Commentary

"The second quarter of 2024 was highlighted by a strong cadence of order growth and revenue as we work toward FDA approvals of next-generation devices and launch of new pain management products," said Thomas Sandgaard, President and CEO of Zynex. "As we have evolved from a small company prior to 2017 to expected revenues of roughly $200 million in 2024, we have taken additional steps during recent quarters to enable us to grow smoothly to a $1 billion company in the longer term. We also continued our share repurchase plan and repurchased $2.2 million of our common stock in Q2 2024 and $70.0 million over the last twenty-four months.

"In the second quarter, increasing sales and profitable growth for our pain management division delivered a 20% improvement in orders year-over-year. Revenue during the quarter was impacted by a continued change in product mix, with sales of our private labeled pain management products growing more than anticipated. While this growth diversifies revenue, these product sales are one-time and lack the trailing revenue model present in our electrotherapy products. In addition, as we emphasize profitable growth, we continued our focus on sales rep productivity and separated more underperforming reps than initially anticipated which decreases near-term revenue but leaves us in a stronger position moving forward.

"With the change in product mix and sales force reduction, we are revising guidance down for the year. We now expect 2024 net revenue to increase approximately 9% compared to 2023. Looking ahead, we continue to focus on diversifying revenue streams with innovative new products and ensuring sustained growth as we build on our holistic, non-invasive approach to pain management. In 2025, we should return to our normal top-line growth in our pain management division of approximately 20%. We look forward to additional updates in the months to come as we work to build long-term value for our shareholders," concluded Sandgaard.

Second Quarter 2024 Financial Results

Net revenue was $49.9 million for the three months ended June 30, 2024, compared to $45.0 million in the prior year quarter, an increase of 11%. The increase in net revenue was primarily related to a 20% growth in device orders which resulted from a larger customer base and led to increased sales of consumable supplies, offset by a reduction in sales representatives and forgoing current sales to focus on profitable growth and rep productivity.

Gross profit in the quarter ended June 30, 2024, was $39.9 million, or 80% of revenue, as compared to $35.7 million or 79% of revenue, in 2023.

Sales and marketing expenses were $23.2 million for the three months ended June 30, 2024, compared to $21.6 million in the prior year period.

General and administrative expenses for the three months ended June 30, 2024, were $14.5 million, versus $11.4 million in the prior year period.

Net income for the three months ended June 30, 2024, totaled $1.2 million, or $0.04 per basic and diluted share, as compared to net income of $3.4 million, or $0.09 per basic and diluted share, in the quarter ended June 30, 2023.

Adjusted EBITDA for the three months ended June 30, 2024, was $3.5 million, as compared to $4.0 million in the quarter ended June 30, 2023.

As of June 30, 2024, the Company had working capital of $55.9 million. Cash and cash equivalents were $30.9 million at June 30, 2024. Cash flow from operations for the six months ended June 30, 2024, was $3.2 million compared to $2.7 million in the six months ended June 30, 2023.

The Company continued its latest stock buyback by repurchasing $2.2 million of its common stock during the second quarter.

Third Quarter and Full Year 2024 Guidance

Third quarter 2024 revenue is estimated to be at least $50.0 million. Third quarter Diluted EPS is estimated to be at least $0.05.

The Company expects 2024 net revenue of at least $200 million, a 9% increase from 2023. Diluted EPS is expected to be at least $0.20 per share.

Conference Call and Webcast Details

Thursday, July 25, 2024, at 4:15 PM Eastern Time (2:15 PM Mountain Time)

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast: Q2 2024 Webcast Link

U.S. & Canada dial-in number: 800-836-8184

International number: 646-357-8785

Non-GAAP Financial Measures

Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense, stock compensation, restructuring, receivables adjustment and non-cash lease charges). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from, or as an alternative to, the financial information prepared in accordance with GAAP.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.

Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; our dependence on third party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy; market conditions; the timing, scope and possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.

These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594

 

ZYNEX, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (AMOUNTS IN THOUSANDS) (unaudited)
		June 30, 2024			December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents		$	30,896		$	44,579
Accounts receivable, net			23,594			26,838
Inventory, net			15,390			13,106
Prepaid expenses and other			4,235			3,332
Total current assets			74,115			87,855
Property and equipment, net			3,250			3,114
Operating lease asset			11,189			12,515
Finance lease asset			785			587
Deposits			409			409
Intangible assets, net of accumulated amortization			7,705			8,158
Goodwill			20,401			20,401
Deferred income taxes			4,061			3,865
Total assets		$	121,915		$	136,904
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses			7,882			8,433
Operating lease liability			3,930			3,729
Finance lease liability			182			196
Income taxes payable			—			633
Accrued payroll and related taxes			6,244			5,541
Total current liabilities			18,238			18,532
Long-term liabilities:
Convertible senior notes, less issuance costs			58,078			57,605
Operating lease liability			12,187			14,181
Finance lease liability			596			457
Total liabilities			89,099			90,775
Commitments and contingencies
Stockholders' equity:
Preferred stock			—			—
Common stock			32			33
Additional paid-in capital			91,963			90,878
Treasury stock, at cost			(87,186)			(71,562)
Retained earnings			28,007			26,780
Total stockholders' equity			32,816			46,129
Total liabilities and stockholders' equity		$	121,915		$	136,904

 

ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2024			2023			2024			2023
NET REVENUE
Devices		$	15,920		$	13,743		$	29,945		$	25,687
Supplies			33,963			31,209			66,469			61,435
Total net revenue			49,883			44,952			96,414			87,122
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies			9,971			9,272			19,269			18,541
Sales and marketing			23,226			21,609			46,606			42,836
General and administrative			14,460			11,358			27,788			22,748
Total costs of revenue and operating expenses			47,657			42,239			93,663			84,125
Income from operations			2,226			2,713			2,751			2,997
Other income (expense)
Gain on disposal of assets			19			—			19			2
Gain on change in fair value of contingent consideration			—			1,700			—			3,100
Interest expense, net			(630)			(317)			(1,142)			(401)
Other income (expense), net			(611)			1,383			(1,123)			2,701
Income from operations before income taxes			1,615			4,096			1,628			5,698
Income tax expense			398			742			401			775
Net income		$	1,217		$	3,354		$	1,227		$	4,923
Net income per share:
Basic		$	0.04		$	0.09		$	0.04		$	0.13
Diluted		$	0.04		$	0.09		$	0.04		$	0.13
Weighted average basic shares outstanding			31,762			36,435			32,053			36,564
Weighted average diluted shares outstanding			32,204			37,061			32,516			37,249

 

ZYNEX, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (AMOUNTS IN THOUSANDS) (unaudited)
		For the Six Months Ended June 30,
		2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	1,227		$	4,923
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			1,329			1,311
Amortization			928			620
Non-cash reserve charges			—			(91)
Stock-based compensation			1,575			967
Non-cash lease expense			(467)			(158)
Benefit for deferred income taxes			(195)			(240)
Change in fair value of contingent consideration			—			(3,100)
Gain on disposal of fixed assets			(19)			(2)
Change in operating assets and liabilities:
Accounts receivable			3,244			2,106
Prepaid and other assets			(805)			(661)
Accounts payable and other accrued expenses			(288)			(1,172)
Inventory			(3,327)			(1,736)
Deposits			—			(92)
Net cash provided by operating activities			3,202			2,675
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(290)			(394)
Proceeds on sale of fixed assets			—			10
Net cash used in investing activities			(290)			(384)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations			(148)			(62)
Cash dividends paid			(3)			(1)
Purchase of treasury stock			(15,625)			(9,468)
Excise tax payments on net treasury stock purchases			(473)			—
Proceeds from issuance of convertible senior notes, net of issuance costs			—			57,026
Proceeds from the issuance of common stock on stock-based awards			13			32
Principal payments on long-term debt			—			(10,667)
Taxes withheld and paid on employees' equity awards			(359)			(546)
Net cash (used in) provided by financing activities			(16,595)			36,314
Net (decrease) increase in cash			(13,683)			38,605
Cash and cash equivalents at beginning of period			44,579			20,144
Cash and cash equivalents at end of period		$	30,896		$	58,749

 

ZYNEX, INC. RECONCILIATION OF GAAP TO NON-GAAP MEASURES (AMOUNTS IN THOUSANDS) (unaudited)
	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
Adjusted EBITDA:
Net income	$       1,217		$      3,354		$       1,227		$      4,923
Depreciation and Amortization*	465		412		891		835
Stock-based compensation expense	841		660		1,575		967
Interest expense and other, net	611		317		1,123		401
Change in value of contingent consideration	—		(1,700)		—		(3,100)
Non-cash lease expense**	—		227		—		227
Income tax expense	398		742		401		775
Adjusted EBITDA	$       3,532		$      4,012		$       5,217		$      5,028
% of Net Revenue	7 %		9 %		5 %		6 %

 

* Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold.

** Amount expensed on new company headquarters in excess of cash payments due to abated rent.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-reports-second-quarter-2024-financial-results-302206996.html

SOURCE Zynex

FAQ

What was Zynex's (ZYXI) revenue for Q2 2024?

Zynex (ZYXI) reported revenue of $49.9 million for Q2 2024, representing an 11% increase year-over-year.

How much did Zynex's (ZYXI) orders grow in Q2 2024?

Zynex's (ZYXI) orders increased by 20% year-over-year in Q2 2024, marking the ninth consecutive quarter of record orders.

What is Zynex's (ZYXI) revenue guidance for full-year 2024?

Zynex (ZYXI) expects net revenue of at least $200 million for full-year 2024, representing approximately 9% growth compared to 2023.

What was Zynex's (ZYXI) earnings per share (EPS) for Q2 2024?

Zynex (ZYXI) reported diluted earnings per share (EPS) of $0.04 for Q2 2024.

How much stock did Zynex (ZYXI) repurchase in Q2 2024?

Zynex (ZYXI) repurchased $2.2 million of its common stock during Q2 2024.